

John Bel Edwards
GOVERNOR



Dr. Courtney N. Phillips
SECRETARY

State of Louisiana

Louisiana Department of Health

Bureau of Health Services Financing

MEMORANDUM

DATE: September 29, 2022

TO: All Louisiana Medicaid Prescribing Providers and Pharmacists

FROM: Tara A. LeBlanc, Medicaid Executive Director DS
TL

SUBJECT: Louisiana Medicaid Pharmacy Point of Sale (POS) Edits for Tramadol/Celecoxib (Seglantis®) - October 2022

Effective October 1, 2022, the Louisiana Medicaid Fee for Service (FFS) Pharmacy Program and Managed Care Organizations (MCOs), in consultation with the Drug Utilization Review (DUR) Board, will implement Point of Sale (POS) edits for tramadol/celecoxib (Seglantis®). The POS edits will apply to pharmacy claims submitted to FFS and MCOs (Aetna, AmeriHealth Caritas, Healthy Blue, Louisiana Healthcare Connections, and UnitedHealthcare).

Pharmacy claims for tramadol/celecoxib (Seglantis®) will have the following POS edits:

- Age Limit (*implemented 7/1/22 as part of edits for all tramadol-containing products*)
- Concurrent Use
- Drug-Drug Interaction
- Maximum Daily Dose
- Morphine Milligram Equivalent (MME) Limit
- Quantity Limit
- Therapeutic Duplication

Point of Sale Concurrent Use of Tramadol/Celecoxib (Seglantis®) with Benzodiazepine

Pharmacy claims for tramadol/celecoxib (Seglantis®) will deny if there is an active claim on the recipient's file for a benzodiazepine. Pharmacy claims for a benzodiazepine will deny if there is an active claim on the recipient's file for tramadol/celecoxib (Seglantis®). Pharmacy claims for these medications will deny at Point-of-Sale (POS) with:

MCO Only: The pharmacy claim will deny with a **NCPDP rejection code**.

FFS Only: **NCPDP rejection code 88** (DUR Reject Error) mapped to **EOB Code 423** (Additive Toxicity)

FFS and MCO POS Edits for Tramadol/Celecoxib (Seglantis®) - October 2022

September 29, 2022

Page 2

Point of Sale Drug-Drug Interaction of Tramadol/Celecoxib (Seglantis®) with Naltrexone

Pharmacy claims for tramadol/celecoxib (Seglantis®) will deny if there is an active claim on the recipient's file for naltrexone. Pharmacy claims for naltrexone will deny if there is an active claim on the recipient's file for tramadol/celecoxib (Seglantis®). Pharmacy claims for these medications will deny at POS with:

MCO Only: The pharmacy claim will deny with a **NCPDP rejection code**.

FFS Only: **NCPDP rejection code 88** (DUR Reject Error) mapped to
EOB Code 471 (Drug-Drug Interaction)

After consultation with the prescriber to verify the necessity of concurrent therapy, the pharmacist may override the denial by submitting the following override at POS:

NCPDP 439-E4 field (Reason for Service Code) **DD** (Drug-Drug Interaction)

NCPDP 440-E5 field (Professional Service Code) **MØ** (Prescriber Consulted)

NCPDP 441-E6 field (Result of Service Code) **1G** (Filled with Prescriber Approval).

Point of Sale Maximum Daily Dose of Tramadol/Celecoxib (Seglantis®)

The maximum daily allowance for tramadol/celecoxib is four (4) tablets per day.

Pharmacy claims submitted for greater than four (4) tablets per day should deny with the following:

MCO Only: The pharmacy claim will deny with a **NCPDP rejection code**.

FFS Only: **NCPDP rejection code 88** (DUR Reject Error) mapped to
EOB Code 529 (Exceeds Maximum Daily Dose)

Point of Sale Morphine Milligram Equivalent (MME) Limit of Tramadol/Celecoxib (Seglantis®)

The cumulative daily MME for all active opioid prescriptions is limited to a maximum of 90 MME per day. Pharmacy claims for tramadol/celecoxib (Seglantis®) which exceed 90 MME per day will deny with:

MCO Only: The pharmacy claim will deny with a **NCPDP rejection code**.

FFS Only: **NCPDP rejection code 88** (DUR Reject Error) mapped to
EOB Code 352 (Over 90MME/Day – Override Using PA Process)

Point of Sale Quantity Limit

The quantity limit for tramadol/celecoxib (Seglantis®) is listed in the chart below.

Medication	Quantity Limit
Tramadol/Celecoxib (Seglantis®)	28 units/7 days for naïve and 45 units/30 days for non-naïve *

**Naïve is defined as having no paid claim for an opioid in the previous 90-days whereas non-naïve is defined by at least one paid claim for an opioid in the previous 90-days.*

FFS and MCO POS Edits for Tramadol/Celecoxib (Seglantis®) - October 2022

September 29, 2022

Page 3

Pharmacy claims, which exceed maximum quantity, will deny with:

MCO Only: The pharmacy claim will deny with a **NCPDP rejection code**.

FFS Only: **NCPDP rejection error 76** (Quantity and/or days' supply exceeds program maximum) mapped to **EOB Code 457** (Quantity and/or days' supply exceeds program maximum).

Override provisions for exceeding the quantity limit should be addressed through the PA process.

Point of Sale Therapeutic Duplication

Pharmacy claims for tramadol/celecoxib (Seglantis®) will deny if there is an active claim on the recipient's file for another short-acting opioid or buprenorphine-containing agent. Conversely, incoming pharmacy claims for a short-acting opioid or buprenorphine-containing agent will deny if there is an active claim on the recipient's file for tramadol/celecoxib (Seglantis®).

Pharmacy claims for medications which hit a therapeutic duplication will deny at (POS) with:

MCO Only: The pharmacy claim will deny with a **NCPDP rejection code**.

FFS Only: **NCPDP rejection code 88** (DUR reject error) mapped to **EOB Code 482** (Therapeutic Duplication)

After consultation with the prescriber, the pharmacist may override the therapeutic duplication by submitting the following at POS in:

NCPDP 439-E4 field (Reason for Service Code) **TD** (Therapeutic Duplication)

NCPDP 440-E5 field (Professional Service Code) **MØ** (Prescriber Consulted)

NCPDP 441-E6 field (Result of Service Code) **1G** (Filled with Prescriber Approval)

Bypass Diagnosis Code Exemptions for tramadol/celecoxib (Seglantis®) Point of Sale Edits (See chart below)

- Pharmacy claims submitted with a diagnosis code for cancer, palliative end-of-life care, second or third degree burns or corruptions, or sickle cell crisis, will bypass tramadol/celecoxib (Seglantis®) quantity limits.
- Pharmacy claims for tramadol/celecoxib (Seglantis®), when submitted with a diagnosis code for cancer, palliative end-of-life care, second or third degree burns or corruptions, or sickle cell crisis, will bypass the maximum morphine milligram equivalent (MME) limit.
- Pharmacy claims for tramadol/celecoxib (Seglantis®), when submitted with a diagnosis code for cancer or palliative end-of-life care, will bypass the restriction on concurrent use of tramadol/celecoxib (Seglantis®) with benzodiazepines.

FFS and MCO POS Edits for Tramadol/Celecoxib (Seglantis®) - October 2022

September 29, 2022

Page 4

Diagnosis Description	ICD-10-CM Diagnosis Code(s)
Cancer	C00.*–C96.*
Palliative Care	Z51.5
Second or Third-Degree Burns or Corrosions	T20.2*, T20.3*, T20.6*, T20.7*, T21.2*, T21.3*, T21.6*, T21.7*, T22.2*, T22.3*, T22.6*, T22.7*, T23.2*, T23.3*, T23.6*, T23.7*, T24.2*, T24.3*, T24.6*, T24.7*, T25.2*, T25.3*, T25.6*, T25.7*
Sickle Cell Crisis	D57.0*, D57.21*, D57.41*, D57.81*

*any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

Additional Information:

FFS Only: Most pharmacy claim denials can be overridden in emergency situations at Point of Sale. If it is necessary to override the claim, “03” can be entered in **NCPDP field 418-DI** (Level of Service). Refer to www.lamedicaid.com for the POS User Guide and override procedures.

MCO Only: If an override is required, or additional assistance needed, contact the health plan. (See contact information at the end of this document.)

Refer to <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf> for the PDL, which is inclusive of the *Louisiana Uniform Prescription Drug Prior Authorization Form*, medication list, and clinical criteria.

If you have questions about the content of this memo, you may contact the FFS pharmacy help desk by phone at (800) 437-9101.

If you have questions about pharmacy claims billing, you may contact the appropriate plan at their pharmacy help desk listed in the chart below.

Healthcare Provider	Pharmacy Help Desk	Pharmacy Help Desk Phone Number
Aetna	CVS Health	(855) 364-2977
AmeriHealth Caritas	PerformRx	(800) 684-5502
Fee for Service	Gainwell Technologies	(800) 648-0790
Healthy Blue	CVS	(833) 236-6194
Louisiana Healthcare Connections	CVS Caremark	(800) 311-0543
UnitedHealthcare	Optum Rx	(866) 328-3108

Please forward this notice to other providers to assist with notification. Your continued cooperation and support of the Louisiana Medicaid Program efforts to coordinate care and improve health are greatly appreciated.

TL/MBW/GJS

c: Healthy Louisiana Plans
Melwyn B. Wendt
Gainwell Technologies